Details of Disease

General Information of Disease (ID: DISUMGPU)

Disease Name Chronic myeloid leukaemia
Disease Class 2A20: Myeloproliferative neoplasm
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISUMGPU: Chronic myeloid leukaemia
ICD Code
ICD-11
ICD-11: 2A20
ICD-10
ICD-10: C92.7
ICD-9
ICD-9: 205.1
Expand ICD-11
XH4XG8
Expand ICD-10
'C92.7
Expand ICD-9
205.1
Disease Identifiers
MONDO ID
MONDO_0004643
MESH ID
D007951
UMLS CUI
C0023470
MedGen ID
7320
HPO ID
HP:0012324
SNOMED CT ID
1163439000

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 4 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Asciminib DM7EVUF Approved Small molecular drug [1]
Dasatinib DMJV2EK Approved Small molecular drug [2]
Imatinib DM7RJXL Approved Small molecular drug [3]
Omacetaxine mepesuccinate DMPU2WX Approved Small molecular drug [4]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ABL 001 DMMF5K4 Phase 3 NA [5]
Galinpepimut-S DMTEQEQ Phase 3 NA [6]
ABIO-05/01 DMJ2U4B Phase 2 NA [7]
HQP1351 DMQ30X2 Phase 2 Small molecular drug [8]
DCC-2036 DMJKFNU Phase 1/2 Small molecular drug [9]
SCO-088 DMRD1IW Phase 1 Small molecular drug [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Drug(s)
This Disease is Treated as An Indication in 4 Patented Agent(s)
Drug Name Drug ID Highest Status Drug Type REF
PMID25656651-Compound-11a DM5ECH2 Patented Small molecular drug [11]
PMID25656651-Compound-11b DMP580J Patented Small molecular drug [11]
PMID25656651-Compound-11c DMAYINQ Patented Small molecular drug [11]
PMID25656651-Compound-5 DMAI95U Patented Small molecular drug [11]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215358.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 078340.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7454).
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 ClinicalTrials.gov (NCT00415909) TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients. U.S. National Institutes of Health.
8 ClinicalTrials.gov (NCT03883100) A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation. U.S. National Institutes of Health.
9 ClinicalTrials.gov (NCT00827138) Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation). U.S. National Institutes of Health.
10 Clinical pipeline report, company report or official report of Sun Pharma Advanced Research Company.
11 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.